Corona Remedies Q2 FY27: revenue up 22.2% to ₹441 Cr, net profit up 15.3% to ₹60 Cr
Results · Finvezto · 2 Nov 2026 · Corona Remedies (CORONA)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 441 | - | +22.2% |
| Operating profit | 96 | - | +22.3% |
| Net profit | 60 | - | +15.3% |
| Operating margin | 21.8% | - | +0.0 pp |
| Net margin | 13.7% | - | -0.8 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Revenue for Q2 FY27 grew by 22.2% year-on-year to INR 441 crores, with the domestic India business contributing 97% of total revenue. Earnings call
- EBITDA for the quarter rose 22.3% year-on-year to INR 96 crores with a stable margin of 21.7%, while profit after tax grew 15.3% to INR 60 crores. Earnings call
- Management reaffirmed its growth outlook of outperforming the Indian pharmaceutical market by 1.5 times, targeting 15% revenue growth and 20% PAT growth. Earnings call
What to watch
- Management on revenue growth: So the estimation of 1.5x in the IPM has always been a guidance, and it will remain as the guidance as far as revenue is concerned.
- Management on wokadine cagr: We are still very confident in achieving 25% CAGR for Wokadine over 3 to 4 years.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.